IMNN: SEC Form 8-K filed by Imunon Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for IMNN
Across the 28 sessions after earlier IMNN headlines, the stock closed higher 9 times and lower 18 times, with a median move of 3.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IMNN | SPY |
|---|---|---|---|
| Oct 21, 2026 | IMUNON Announces Strategic Sale of ThermoDox® | +18.4% | +0.5% |
| Oct 8, 2026 | IMUNON to Participate in Upcoming Investor Conferences | -6.1% | -0.4% |
| Sep 29, 2026 | IMUNON Converts $1.2 Million of Debt-to-Equity | -3.3% | -0.2% |
| Sep 24, 2026 | IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan | -8.2% | -0.1% |
| Sep 22, 2026 | IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review | +5.6% | -0.0% |
| Sep 10, 2026 | IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 | -4.0% | -0.6% |
Quantisnow market dataNASDAQ
IMNN
Imunon Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for IMNN
Full IMNN profile on Quantisnow Follow IMNN and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time